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Objectives The aim of this study was to assess the association between genetic variants of the insulin receptor substrate
(IRS)-1 gene, platelet function, and long-term outcomes in patients with type 2 diabetes mellitus (DM) and sta-
ble coronary artery disease while on aspirin and clopidogrel therapy.
Background The effects of pharmacogenetic determinants on platelet function and cardiovascular outcomes in type DM pa-
tients are unknown.
Methods The association between IRS-1 genetic variants, platelet function, and the risk of major adverse cardiac events
(MACE) at 2 years was assessed in 187 patients with type 2 DM and stable coronary artery disease on mainte-
nance aspirin and clopidogrel therapy.
Results Seven tag single nucleotide polymorphisms were selected. Individuals with high platelet reactivity were more frequent
among carriers of the C allele (GC and CC genotypes; approximately 20% of population) of the rs956115 marker
(44.4% vs. 20.5%; odds ratio: 3.1, 95% confidence interval [CI]: 1.44 to 6.67; p  0.006). These patients were at
higher risk of MACE (28.0% vs. 10.9%; hazard ratio: 2.90, 95% CI: 1.38 to 6.11; p  0.005). The C allele carriers of
the rs956115 marker were more commonly associated with a hyperreactive platelet phenotype. This was confirmed
in an external validation cohort of patients with type 2 DM but not in an external validation cohort of patients without
DM. Carriers of the C allele of the rs956115 marker also had a significantly higher risk of MACE compared with non-
carriers (30.6% vs. 11.4%; hazard ratio: 2.88, 95% CI: 1.35 to 6.14; p  0.006).
Conclusions Type 2 DM patients who are carriers of the C allele of the rs956115 marker of the IRS-1 gene have a hyper-
reactive platelet phenotype and increased risk of MACE. (J Am Coll Cardiol 2011;58:30–9) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.040Dual antiplatelet therapy with aspirin and clopidogrel is the
recommended treatment for patients with acute coronary
syndromes (ACS) and in those undergoing percutaneous
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June 28, 2011:30–9 Gentics, Diabetes, and Outcomeson-treatment platelet reactivity (HPR) have an increased
risk of ischemic events (3,4). Patients with diabetes mellitus
(DM) have a greater prevalence of HPR compared with
non-DM, which might explain their overall enhanced risk
of developing atherothrombotic complications (5–8). How-
ever, heterogeneous antiplatelet drug effects might also be
observed among patients with DM, and platelet function
profiling even within this high-risk cohort identifies subjects
at a greater risk of recurrent ischemic events (9). The
mechanisms leading to variable antiplatelet drug response
profiles in patients with DM are not fully elucidated.
Although there is growing evidence that single nucleotide
polymorphisms (SNPs) might modulate antiplatelet drug
effects (10), whether these might explain the heterogeneity
in response profiles and clinical outcomes selectively in
patients with DM remain unexplored.
Human platelets are targets of insulin effects that are
mediated by the insulin receptor substrate (IRS)-1 (8,11). In
healthy volunteers, insulin interferes with calcium increases
induced by adenosine diphosphate (ADP)-P2Y1 contact
hrough Gi activity and, thereby, with P2Y12-mediated
uppression of cyclic adenosine monophosphate (cAMP)
11). However, platelets from patients with type 2 DM have
ost responsiveness to insulin, leading to increased P2Y12-
ediated suppression of cAMP and decreased antiplatelet
rug effects (12). Importantly, studies performed in subjects
ithout DM or in a pre-DM status have shown that gene
equence variations of IRS-1 are associated with the func-
ional activity of this receptor (13) as well as being a risk
actor for coronary artery disease (14). However, whether
RS-1 genotypes are associated with variations in antiplate-
et drug response profiles and whether these might impact
linical outcomes in patients with DM is unknown. To
ddress this issue we evaluated whether IRS-1 genotypes
ere associated with platelet function profiles and cardio-
ascular outcomes.
ethods
tudy population. Blood samples for platelet function
nalyses and genotyping were collected from a total of 208
edically treated (with oral hypoglycemic agents and/or
nsulin) patients with type 2 DM and stable coronary artery
isease from November 2003 to March 2007. To avoid
tratification of the sample due to ethnicity, only Caucasian
atients homogeneous for ethnic background were included.
ll patients (primary cohort as well as 2 external validation
ohorts) were from the central regions of Spain. To be
ligible, patients with type 2 DM (18 years of age) needed
o have undergone PCI and been receiving aspirin and
lopidogrel therapy for 6 to 9 months in the absence of
ardiovascular events during this period. Type 2 DM was
efined according to the World Health Organization Re-
ort (15). All patients were recruited from the outpatient
linic of our hospital as part of their routine follow-up after
CI. Aspirin (100 mg/day) was used indefinitely, andlopidogrel (75 mg/day) was pre-
cribed for 12 months after cor-
nary revascularization. Blood
ampling was not performed if 1
f the following exclusionary cri-
eria was present: 1) use of anti-
latelet agents other than aspirin
nd clopidogrel; 2) use of oral
nticoagulants; 3) occurrence of
n acute cardiovascular event
uring the interval between PCI
nd blood sampling; 4) impaired
lucose tolerance without phar-
acologic treatment, gestational
iabetes, or transient hyperglyce-
ia; 5) platelet count 125.000/
m3; 6) hematocrit 25%; 7)
creatinine levels 2.5 mg/dl; or
8) hepatic enzymes (alanine ami-
notransferase or aspartate amino-
transferase) twice the upper nor-
mal limit.
Patients meeting study eligi-
bility criteria were followed for
24 months, and clinical events
were recorded. Follow-up was
performed by means of telephone
contacts every 6 months and clinic visits on a yearly basis.
Patients with nonvaluable pharmacodynamic assessments
were excluded from the final analysis. The primary outcome
measure was a composite of cardiovascular death, ACS
leading to hospital stay, and nonfatal stroke. Such major
adverse cardiovascular events (MACE) were defined ac-
cording to definitions proposed by the American College of
Cardiology (see the Online Appendix for complete descrip-
tion) (16). The treating physicians and investigators who
adjudicated the clinical endpoints were blinded to the results
of the pharmacodynamic and genotype assessments.
After our initial investigation to define the prevalence and
functional impact of IRS-1 genotypes in our main study
cohort, validation assessments were performed to replicate
the pharmacodynamic findings associated with the carrier
status of the C allele of the rs956115 marker, which
emerged from the main cohort to be associated with a
hyperreactive platelet phenotype. In particular, a separate
external cohort of patients with type 2 DM (n  52)
undergoing elective PCI was identified to confirm the
pharmacodynamic impact of this marker in the acute phase
of clopidogrel therapy. All patients were taking aspirin
therapy and received a 600-mg loading dose of clopidogrel
at the time of intervention; pharmacodynamic assessments
were performed at hospital discharge. Furthermore, to
determine whether or not the pharmacogenetic findings
were specific to patients with DM, a pharmacodynamic
assessment was also extended to a cohort of patients without
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ADP  adenosine
diphosphate
CI  confidence interval
CYP  cytochrome P450
DM  diabetes mellitus
HbA1C  hemoglobin A1C
HPR  high platelet
reactivity
HR  hazard ratio
IRS  insulin receptor
substrate
LD  linkage disequilibrium
MACE  major adverse
cardiovascular event(s)
OR  odds ratio
PCI  percutaneous
coronary intervention
ROC  receiver-operator
characteristic
SNP  single nucleotide
polymorphismDM (n  90). Similarly, to study subjects from the main
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Gentics, Diabetes, and Outcomes June 28, 2011:30–9cohort, these patients were in their steady state phase of the
same doses of aspirin and clopidogrel therapy. A flow
diagram of the main study cohort and separate external
validation cohorts is provided in the Online Appendix
(Online Fig. 1).
The study complied with the Declaration of Helsinki and
was approved by the Ethical Committee of the San Carlos
University Hospital, and all patients gave their informed
consent.
Pharmacodynamic assessments. Pharmacodynamic effects
were assessed with light transmittance aggregometry ac-
cording to standard protocols, as previously described (see
the Online Appendix for complete description) (5,6,9).
Maximum platelet aggregation was measured after stimuli
with ADP (20 mol/l) to assess purinergic mediated plate-
et function. High platelet reactivity was defined as the
pper quartile of ADP-induced aggregation, as previously
escribed (9,17,18). To define nonpurinergic mediated
latelet function, platelet aggregation after collagen (6 g/ml)
timuli was also performed (6,9).
enotyping and haplotype association analyses. Genomic
eoxyribonucleic acid was extracted from peripheral-blood
eucocytes with standard salting-out procedures. The se-
ection of the tag SNPs of IRS-1 gene was performed
ith GEVALT 2.0 software (GEnotype Visualization and
Lgorithmic Tool) (19–21). The SNP genotype data for
tah residents with ancestry from northern and western
urope (CEU) population were downloaded from HapMap
roject Browser, submitting a 100-kilobase pair region as a
uery (chr2: 227,290,450..227,390,449; release April 2007).
ecause rs1801278 has been extensively investigated in the
ublished data, this was force-included in the list of tag
NPs identified (13,14). The 7 tag SNPs gave an estimated
rediction value of 97.6% for the IRS-1 genomic region
nvestigated. Genotyping was performed with FRET (Flu-
rescent Resonance Energy Transfer) Probes technology on
he LightCycler 2.0 instrument (Roche Diagnostics, Basel,
witzerland) and TaqMan SNP Genotyping assays on and
pplied Biosystems StepOnePlus instrument (Applied Bio-
ystems, Foster City, California) (see the Online Appendix
or complete description). Lewontin’s D= and the square of
orrelation coefficient r between 2 markers were used as a
easure of linkage disequilibrium (LD) of all marker pairs
22). The LD haplotype block structure was identified with
EVALT 2.0 according to the gerbil algorithm (20).
aplotype association analyses were performed on the
ntire haplotype region (i.e., including the 7 tag SNPs) and
n subregions defined by LD blocks (23).
tatistical analysis. Continuous variables were analyzed
or a normal distribution with the Kolmogorov-Smirnov
est and presented as mean  SD or median and interquar-
ile range, as appropriate. Normally distributed variables
ere analyzed with Student t tests, whereas the Mann-
hitney U test was used for comparisons of non-normally
distributed variables. Categorical variables are presented as
frequencies and percentages and were compared with theuse of chi-square test or Fisher exact test where appropriate.
Receiver-operator characteristic (ROC) analyses were per-
formed for an exploratory evaluation of the optimal cutoff
value of ADP- and/or collagen-induced platelet aggregation
for predicting MACE in our study population (9,24).
Spearman’s rank correlation was used to examine the cor-
relation between profiles of platelet reactivity and glycemic
control, defined by hemoglobin A1C (HbA1C) levels.
Interaction among genotype, insulin resistance (defined by
homeostatic model assessment; see Online Appendix for
description), and HPR was also determined. Rates of the
primary endpoint are expressed as Kaplan-Meier estimates
at 24 months and compared with log rank testing. Univari-
able and multivariable Cox proportional hazards regression
models were used to assess unadjusted and adjusted risk of
the combined cardiovascular endpoint associated with HPR
and genotype. Demographic, clinical, and laboratory vari-
ables provided in Table 1 were entered in the Cox model for
the multivariable analysis, and those that were not signifi-
Baseline Demographic Data and ClinicalCharacteristics According to Post-TreatmentPlat le Reactivity Status
Table 1
Baseline Demographic Data and Clinical
Characteristics According to Post-Treatment
Platelet Reactivity Status
Variable
HPR
(n  47)
No HPR
(n  140) p Value
Age (yrs) 64 10 67 10 0.15
Male 31 (66) 101 (72) 0.54
Risk factors/past medical history
Insulin-treated diabetes 20 (43) 41 (29) 0.13
HbA1C 7.4 1.3 7.1 1.1 0.18
Smoking 9 (19) 19 (14) 0.49
Hyperlipidemia 30 (64) 106 (76) 0.16
Hypertension 31 (66) 91 (65) 0.95
Body mass index (kg/m2) 28.3 4.1 28.8 3.7 0.44
Obesity (body mass index 30 kg/m2) 19 (40) 52 (37) 0.82
Prior cerebrovascular event 0 6 (4) 0.34
Peripheral vascular disease 4 (9) 16 (11) 0.79
Chronic renal dysfunction 10 (21) 37 (26) 0.61
Left ventricular dysfunction 7 (15) 27 (19) 0.65
Prior myocardial infarction 31 (66) 75 (54) 0.19
Prior CABG 1 (2) 3 (2) 1.00
Multivessel CAD 34 (72) 99 (71) 0.98
Treatment*
Beta-blockers 29 (62) 105 (75) 0.12
Calcium-channel blockers 9 (19) 40 (29) 0.28
Nitrates 21 (45) 59 (42) 0.89
ACE inhibitors/ARB 24 (51) 78 (56) 0.70
Statins 39 (83) 110 (79) 0.92
CYP3A4-metabolizing statin 32 (82) 95 (86) 0.88
Non–CYP3A4-metabolizing statin 7 (18) 15 (14) 0.61
Proton pump inhibitors 39 (83) 108 (77) 0.52
Values are n (%) or mean  SD. *Aspirin and clopidogrel were used in all (100%) patients. There
ere no differences in length of clopidogrel therapy between high on-treatment platelet reactivity
HPR) and non-HPR groups (total duration: 12 months; post platelet function assessment: 4.78 
.49months vs. 4.63 1.50months, p 0.53). Among noninsulin-treated diabetic subjects, there
ere no differences in type of oral hypoglycemic agents used between HPR and non-HPR groups.
ACE angiotensin-converting enzyme; ARB angiotensin II receptor blockers; CABG coronary
rtery bypass grafting; CAD  coronary artery disease; CYP  cytochrome P450; HbA1C 
emoglobin A1C.cant at p  0.10 were removed by a backward stepwise
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June 28, 2011:30–9 Gentics, Diabetes, and Outcomeselimination. With this method, chronic renal insufficiency
was identified as the only significant predictor associated
with the primary endpoint. The HPR and genotype were
added as independent categorical variables in the model,
including chronic renal insufficiency as variable for statistical
adjustment. The assumption of proportional hazard was
checked with time-dependent covariates and was found to
be reasonable. First order interactions were evaluated. Haz-
ard ratios (HRs) and 95% confidence intervals (CIs) were
calculated. Odds ratios (ORs) are provided for the associa-
tion between ADP and/or collagen-induced aggregation
above the upper quartile with the genotype. A p value0.05
was considered statistically significant for all the tests
mentioned in the preceding text. Statistical analysis was
performed with SPSS software (version 14.0, SPSS, Inc.,
Chicago, Illinois).
Hardy-Weinberg equilibrium was evaluated for each tag
SNP, and markers were rejected if they violated Hardy-
Weinberg equilibrium with a threshold of p  0.01.
onferroni correction was applied to adjust the nominal
ignificance level of the association test of HPR status with
ach of the 7 tag SNPs (p  0.05/7  0.007). A multivari-
ble logistic regression analysis, including the genotype
long with all the covariates that might impact the degree of
latelet aggregation, was performed to assess the adjusted
R for ADP and/or collagen-induced aggregation above
he upper quartile, associated with the genotype. The ADP
nd/or collagen-induced aggregation above the upper quar-
ile were treated as a dependent variable, and age, sex, body
ass index, diabetes status (insulin- or noninsulin-treated),
yperlipidemia, hypertension, smoking, HbA1C, renal in-
ufficiency, and concomitant medications were included into
he statistical model as covariates. All probability values
eported are 2-sided, and a value of p 0.05 was considered
o be significant. The SNPs showing significant associations
p 0.05) were then tested for recessive or dominant model
i.e., grouping the heterozygotes together with homozygotes
or the major allele or for the minor allele, according with
he model).
Generalized linear models were used to assess haplotype
ssociations while adjusting for the effects of nongenetic
ofactors. The null hypothesis of no haplotype effects was
ested by standard methods that compare the deviances of
he model including or not including genetic data (global
est). The significance of the effect of each individual
aplotype was also tested (individual haplotype test). Asso-
iation of individual haplotypes was considered significant
hen both p values of global and at least 1 of the individual
aplotype tests were below a threshold value (p  0.05).
he effect of each haplotype was assumed to be additive
i.e., a linear increase in log-odds). Haplotypes whose
stimated frequency was 0.01 were grouped into “rare”
aplotypes and then treated as a single haplotype. Haplo-
ype association analyses were computed with the R soft-
are (R Foundation for Statistical Computing, Vienna,
ustria) and the library “haplo.stats” (25). (We estimated that this study has enough statistical power
beta  0.80) to detect an association between HPR
defined as ADP-induced platelet aggregation 64%) and
n SNP at the significance level of 0.05 under the hypoth-
sis that the risk allele has a frequency of 10% and is in
bsolute LD (D=  1) with the causative variant and that
he OR of the carrier of the risk allele versus noncarrier is
2.8. The number of patients determined to be included in
he validation samples was approximately one-third of the
umber of patients included in the main cohort, as previ-
usly established (26).
esults
haracteristics of the patients and platelet reactivity. Of
he 208 patients enrolled in the main cohort of the present
tudy, pharmacodynamic and genotype assessments were
oth available in 187 (89.9%), who were therefore consid-
red for the present analysis. The remaining 21 patients
10.1%) were excluded, due to inability to measure platelet
ggregation for reasons including hemolysis, low platelet-
ich-plasma platelet counts (150,000/l), and instability
f tracings. In the overall study population, ADP-induced
latelet aggregation was 55  15% and followed a normal
ell-shaped distribution indicative of a heterogeneous re-
ponse profile. The ADP-induced platelet aggregation
uartile cut points for the 25th, 50th, and 75th percentiles
f the study population were 45.0%, 55.0%, and 64.0%. The
PR was defined as ADP-induced platelet aggregation
64%. Baseline demographic data and clinical characteris-
ics of patients with (n  47) and without (n  140) HPR
re provided in Table 1. Insulin-treated diabetic subjects
ere more frequent in the HPR group, although no
tatistically significant differences were found. Also, there
ere no significant differences between groups for all other
ariables. In the overall population, collagen-induced aggre-
ation was 45 19%. Quartile cut points for the 25th, 50th,
nd 75th percentiles were 33.0%, 46.0%, and 59.0%, respec-
ively. Collagen-induced aggregation was 58  15% versus
1  18% in patients with and without HPR defined with
DP stimuli, respectively (p  0.0001). Among patients
ith HPR, 55.3% had collagen-induced aggregation above
he 75th percentile.
RS-1 genotypes and platelet reactivity. Seven tag SNPs
rs11683087, rs2251692, rs1801278, rs1801123, rs6725330,
s1896832, rs956115) with an estimated prediction value of
7.6% were selected. None of these 7 SNPs showed
eviation from Hardy-Weinberg equilibrium, and their
requencies were similar to those reported in the Utah
esidents with ancestry from northern and western Europe
opulation. Table 2 summarizes marker information and
he observed genotype frequencies for the 7 tag SNPs
ssessed. Of the 7 tag SNPs, only the rs956115 marker
howed a significant association with HPR. Individuals with
PR were more frequent among carriers of the C alleleGC and CC genotypes) of the rs956115 marker (44.4% vs.
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Gentics, Diabetes, and Outcomes June 28, 2011:30–920.5%; OR 3.1, 95% CI: 1.44 to 6.67; p 0.006) (Fig. 1A),
hich remained statistically significant when applying the
onferroni correction (p  0.007 required for significance).
his association was also confirmed in an adjusted regres-
ion analysis (adjusted OR: 3.56, 95% CI: 1.51 to 8.38; p 
.004). The prevalence of C allele carriers of the rs956115
arker increased across quartile distribution of ADP-
nduced aggregation (Fig. 1B). There was no correlation
etween ADP- (r  0.092, p  0.210) and collagen-
nduced (r  0.094, p  0.200) platelet reactivity and
bA1C levels. Furthermore, there was no interaction be-
ween C carrier status of the rs956115 marker and insulin
esistance in determining HPR (p for interaction  0.419).
roportions of patients with HPR after collagen and ADP-
nd collagen-induced stimuli are reported in Table 3.
In the external validation cohort of patients with type 2
M, C allele carriers of the rs956115 marker represented
9.2% of the patient population. These patients were
reated with a 600-mg loading dose of clopidogrel, resulting
n more suppressed platelet reactivity compared with pa-
ients from the main cohort who were receiving mainte-
ance therapy. The ADP- and collagen-induced platelet
Tag SNPs From the IRS-1 GeneRe ion and Genotype Frequ cyTable 2 Tag SNPs From the IRS-1 GeneRegion and Genotype Frequency
Tag SNP Position
Alleles Genotypes
Major (M)/
Minor (m) MM Mm mm
rs11683087 227294850 A/G 145 (77.5) 41 (21.9) 1 (0.5)
rs2251692 227298024 G/A 129 (69.0) 53 (28.3) 5 (2.7)
rs1801278 227368788 G/A 109 (58.3) 59 (31.5) 19 (10.2)
rs1801123 227369287 A/G 153 (81.8) 31 (16.6) 3 (1.6)
rs6725330 227375101 A/G 147 (78.6) 37 (19.8) 3 (1.6)
rs1896832 227380730 A/G 164 (87.7) 21 (11.2) 2 (1.1)
rs956115 227382808 G/C 151 (80.7) 33 (17.6) 3 (1.6)
Values are n (%), unless otherwise indicated. Position  position (nucleotides) on chromosome 2
according to single nucleotide polymorphism database (dbSNP) (Map to Genome Build:36.3).
IRS  insulin receptor substrate; MM  homozygote for major (most frequent) allele M; Mm 
heterozygote; mm  homozygote for minor allele m.
Figure 1 Prevalence of High On-Treatment Platelet Reactivity A
Carriers of the C allele (GC and GG genotypes; solid bars) of the rs956115 genoty
on-treatment platelet reactivity compared with noncarriers (GG genotype; open bar
tion of platelet reactivity (B).ggregation values after clopidogrel loading dose adminis-
ration were 30.7  29.5% and 25.9  24.2%, respectively.
roportions of patients with HPR after ADP, collagen, and
oth ADP- and collagen-induced stimuli were significantly
reater among carriers of the C allele of the rs956115
arker (Table 3). In the external validation cohort of
atients without DM in their steady state phase of dual
ntiplatelet therapy, C allele carriers of the rs956115 marker
epresented 31.1% of the patient population. The ADP-
nd collagen-induced platelet aggregation were 53.2 
6.5% and 41.0  19.7%, respectively. Although there was
greater prevalence of patients with HPR among patient
ho were carriers of the C allele of the rs956115 marker,
his was not statistically significant (Table 3).
RS-1 haplotypes and platelet reactivity. The IRS-1 gene
aplotypes were inferred from the 7 tag SNPs (Online
able 7). Haplotype association tests were conducted on the
rimary sample (208 individuals) in which there was no
ignificant association between any of these inferred haplo-
ypes and the phenotypes investigated in this study (data not
hown). Three haplotype LD blocks were identified in the
enotyped sample for the IRS-1 gene region: block-1
rs11683087-rs2251692), block-2 (rs1801278-rs1801123-
s6725330), and block-3 (rs1896832-rs956115) (see Online
able 8 for frequencies, Online Fig. 2 for pairwise LD
tructure, and Online Table 9 for LD measures). Haplotype
D block analyses showed no significant associations for
lock-1 or block-2 with any of the phenotypes investigated.
here was a significant association between haplotypes of
D block-3 (rs1896832-rs956115) and HPR (global p 
.036); a trend was observed with ADP- and collagen-
nduced aggregation above the upper quartiles (global p 
.09). Haplotype rs1896832-A/rs956115-C showed a sig-
ificant association with HPR (adjusted OR: 2.63; CI: 1.26
o 5.48; p  0.01) and ADP- and collagen-induced aggre-
ation above the upper quartiles (adjusted OR: 2.36; CI:
.02 to 5.47; p  0.045).
ding to rs956115 Genotypes of the IRS-1 Gene
the insulin receptor substrate-1 (IRS-1) gene have a greater prevalence of high
The prevalence of carriers of the C allele increases across quartile (Q) distribu-ccor
pe of
s) (A).
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June 28, 2011:30–9 Gentics, Diabetes, and OutcomesPlatelet reactivity and clinical outcomes. Major adverse
cardiovascular events occurred in a total of 28 patients (15%)
during the 24-month follow-up period. Major adverse
cardiovascular events were largely driven by ACS requiring
hospital stay (n  26; 93%); 2 patients experienced a
cardiovascular death and a nonfatal ischemic stroke. There
were a total of 4 noncardiac deaths. Patients with HPR were
at significantly higher risk of MACE (28.0% vs. 10.9%;
HR: 2.90, 95% CI: 1.38 to 6.11; p  0.005) (Fig. 2). A
significant association between HPR and MACE was
confirmed in the multivariable analysis (adjusted HR: 3.10,
95% CI: 1.47 to 6.52; p  0.003). In patients with HPR, a
rend toward a higher risk of MACE was observed during
lopidogrel treatment (6.4% vs. 2.1%; p  0.16), whereas
ifferences in outcomes were statistically significant after its
ithdrawal (26.8% vs. 9.8%; p  0.01). A higher risk of
ACE was seen in patients in the upper quartile of
ollagen-induced aggregation (23.9% vs. 12.3%; HR: 2.13,
5% CI: 1.00 to 4.55; p  0.051; adjusted HR: 2.18, 95%
I: 1.02 to 4.67; p  0.044) and in patients with both
ADP- and collagen-induced aggregation above the upper
quartiles (35.2% vs. 11.9%; HR: 3.49, 95% CI: 1.58 to 7.71;
p  0.002; adjusted HR: 3.71, 95% CI: 1.67 to 8.25;
p  0.001) (Fig. 2). The upper quartiles of ADP- and
collagen-induced platelet aggregation were found to be the
best predictors of MACE in the ROC analyses.
IRS-1 genotypes and clinical outcomes. Carriers of the C
allele of the rs956115 marker had a significantly higher risk
of MACE (30.6% vs. 11.4%; HR: 2.88, 95% CI: 1.35 to
6.14; p  0.006) (Fig. 3). Carriers of the C allele had a
nonsignificant increase in MACE while receiving clopi-
dogrel treatment (5.6% vs. 2.6%; p  0.39). Major adverse
Prevalence of Patients With HPR Among Carrierof the C Allele of the rs956115 MarkerTable 3 Preval ce of Patients With HPR Aof the C Allele of the rs956115 Ma
Patients With HPR
Prim
Total
(n  187)
Carriers
(n  36)
After ADP 47 (25.1) 16 (44.4)
After collagen 47 (25.1) 14 (38.9)
After ADP and collagen 26 (13.9) 10 (27.8)
Validation Coho
Total
(n  52)
Carriers
(n  10)
After ADP 4 (7.7) 3 (30.0)
After collagen 9 (17.3) 6 (60.0)
After ADP and collagen 2 (3.8) 2 (20.0)
Validation Cohor
Total
(n  90)
Carriers
(n  28)
After ADP 23 (25.6) 10 (35.7)
After collagen 18 (20.0) 8 (28.6)
After ADP and collagen 14 (15.6) 6 (21.4)
Values are n (%). *The p values are calculated with the use of chi-squ
ADP  adenosine-diphosphate; CI  confidence interval; DM  diacardiovascular events increased over time after clopidogrelwithdrawal in C allele carriers (31.2% vs. 9.9%; p  0.005)
(see Online Fig. 3 for landmark analysis). In the multivari-
able analysis, the C allele of the rs956115 marker showed to
be an independent predictor of MACE both in the model
not including (adjusted HR: 3.11, 95% CI: 1.45 to 6.68;
p  0.004) and in that including HPR (adjusted HR: 2.31,
95% CI: 1.03 to 5.19; p  0.04) as a covariate. There were
no differences in baseline demographic data and clinical
characteristics of patients with (n  36) and without (n 
151) the C allele of the rs956115 marker (Online Table 10).
There was no interaction according to insulin usage on
HPR (p for interaction  0.58) and MACE (p for inter-
action  0.82) (Online Table 11). There was a significant
association between haplotypes of LD block-3 (rs1896832-
rs956115) and MACE (global p  0.028). Haplotype
rs1896832-A/rs956115-C showed a significant association
with MACE (adjusted OR: 3.0, 95% CI: 1.36 to 6.7; p 
0.007).
Discussion
This is the first study to evaluate the impact of gene
sequence variations on antiplatelet drug effects and clinical
outcomes in patients with DM. In particular, the results of
the present study demonstrate that, in patients with type 2
DM and stable coronary artery disease, gene sequence
variations of IRS-1—namely C allele carriers of the
rs956115 polymorphism (observed in approximately 20% of
patients)—associate independently with a hyperreactive
platelet phenotype and enhanced long-term cardiovascular
risk. These findings not only provide further insights on
pharmacogenetic modulation of antiplatelet drug effects but
NoncarriersCarriers and Noncarriers
ohort
OR (95% CI)
Noncarriers
(n  151) p Value*
31 (20.5) 0.006 3.10 (1.44–6.67)
33 (21.9) 0.058 2.28 (1.05–4.93)
16 (10.6) 0.01 3.25 (1.33–7.93)
atients With DM
Noncarriers
(n  42) p Value*
1 (2.4) 0.02 17.6 (1.59–193.88)
3 (7.1) 0.001 19.5 (3.47–109.57)
0 0.03 —
tients Without DM
Noncarriers
(n  62) p Value*
13 (21.0) 0.22 2.09 (0.78–5.61)
10 (16.1) 0.28 2.08 (0.72–6.02)
8 (12.9) 0.35 1.84 (0.57–5.92)
t or Fisher exact test as appropriate.
ellitus; HPR  high platelet reactivity; OR  odds ratio.s andmong
rker
ary C
rt of P
t of Paalso provide a genetic explanation as to why variable clinical
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with DM homogeneous for baseline risk profile.
Variability in individual response to antiplatelet therapy is
an emerging clinical entity (3,4). The mechanisms leading
to antiplatelet drug response variability are not fully estab-
lished and are likely multifactorial (3,4). Pharmacogenetics
has recently emerged as a field that tries to explain this
phenomenon (10). Recent findings have shown genetic
targets modulating pharmacokinetic profiles of clopidogrel
through its metabolism by the cytochrome P450 (CYP)
enzymatic system to have a major role on its pharmacody-
namic effects (27–32). This might explain why recent
studies have shown that gene sequence variations of
CYP2C19 are associated with an increased risk of adverse
events in clopidogrel-treated patients (30–35). However,
gene sequence variations of CYP2C19 contribute to only
approximately 12% of the interindividual response profile to
clopidogrel (32), and these findings cannot be extrapolated
to patients with DM who have specific aberrations in their
platelet function compared with patients without DM,
leading to differences in pharmacodynamic profiles that are
ultimately determinants of thrombotic mediated processes
(5–8). In fact, in vitro and ex vivo studies have shown that
reduced pharmacodynamic effects of antiplatelet agents in
patients with DM are attributed to upregulation of platelet
signaling pathways (5–9,12), suggesting the potential mod-
ulating role of genetic determinants of “downstream” (e.g.,
platelet membrane receptors) mediators of platelet reactiv-
ity. Although glycemic control is known to be associated
with platelet reactivity through various mechanisms, includ-
ing glycation of platelet surface proteins (36), in our study
Figure 3 Association Between rs956115 Genotype Status
and Major Adverse Cardiac Events
Among 187 type 2 diabetic patients who were classified as carriers (GC and
GG genotypes) or noncarriers (GG genotype) of the rs956115 genotype of the
insulin receptor substrate-1 (IRS-1) gene, the rate of major adverse ischemic
events (composite of CV death, ACS, or stroke) was 30.6% among carriers as
compared with 11.4% among noncarriers (HR: 2.88, 95% CI: 1.35 to 6.14).
Abbreviations as in Figure 2.Figure 2 Association Between Profiles of Platelet Reactivity
and Major Adverse Cardiac Events
Among 187 type 2 diabetic patients who were classified as having high
on-treatment platelet reactivity (HPR) after adenosine diphosphate (ADP) (A),
collagen (B), or both (C) stimuli, the rate of major adverse ischemic events
(composite of cardiovascular [CV] death, acute coronary syndrome [ACS], or
stroke) was greater compared with those without (ADP: 28.0% vs. 10.9%, haz-
ard ratio [HR]: 2.90, 95% confidence interval [CI]: 1.38 to 6.11; collagen:
23.9% vs. 12.3%, HR: 2.13, 95% CI: 1.00 to 4.55; ADPcollagen: 35.2% vs.
11.9%; HR: 3.49, 95% CI: 1.58 to 7.71).this was not observed—likely because patients in our study
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HbA1C levels, as also shown in prior investigations (5,6).
The impact of downstream genetic determinants are sup-
ported by our study findings in which IRS-1 genotypes were
associated with a hyperreactive platelet phenotype in pa-
tients with type 2 DM but not in those without this
metabolic disorder. These pharmacodynamic effects were
confirmed irrespective of whether patients were in the acute
phase of treatment after a high loading dose regimen or in
the maintenance phase of dual antiplatelet therapy. A high
loading dose of clopidogrel in patients undergoing PCI
leads to enhanced platelet inhibitory effects with a broader
range of variability compared with patients in their long-
term maintenance of standard dosing (3), as also shown in
this study. More variable profiles of platelet reactivity
enables better identification of whether there are specific
factors associated with poor response. This might explain
why the ORs of having a hyperreactive platelet phenotype
among carriers of the C allele of the rs956115 marker were
higher in the acute phase of therapy compared with the
maintenance phase.
The present study further supports the prognostic impli-
cations associated with a hyperreactive platelet phenotype
(3,4). Of note, the magnitude of effect on clinical outcomes
(approximately 3-fold increase in MACE) observed in our
study was of the same extent or even greater than that
observed in recent CYP2C19 studies (31–35). It should be
underscored that the latter were performed in ACS patients,
many undergoing PCI, in whom most events occurred early
and survival curves paralleled over time, suggesting a prog-
nostic role of CYP2C19 gene variants for early but not late
events. In contrast, in our analysis, we studied stable
patients—in a period remote from when recurrent events
most commonly occur (6 to 9 months after PCI)—and
showed that survival curves diverge over time. Previous
studies, performed primarily in subjects without DM or in
pre-DM states, have shown functional polymorphisms of
the IRS-1 gene to modulate insulin sensitivity (13) as well
as to be a risk factor for coronary artery disease (14). In our
study population of patients with type 2 DM, however, we
did not find any interaction among the rs956115 marker,
degree of insulin resistance, and platelet reactivity. Because
the rs956115 polymorphism is located in the 5’ region of the
IRS-1 gene, this does not affect amino acid coding and does
not directly affect protein function. Therefore, our findings
might be due to a linkage with other SNPs in exons
(resulting in functional polymorphism) or in regulatory
regions (affecting the expression of IRS-1 gene). The
complexity of intraplatelet signaling and the potential for
interplay with other pathways that derives from IRS-1
suggest that, although levels of insulin sensitivity remain a
contributor to platelet function profiles, many other mech-
anisms might be involved in determining a hyper-reactive
platelet phenotype as a consequence of a dysfunction of
IRS-1–mediated signaling. Because the rs956115 C allele
was an independent predictor of clinical outcomes afteradjustment for potential confounders (with and without
HPR as a covariate), other unknown reasons that are not
entirely linked to HPR might be implied and warrant
further investigation.
Although loss of responsiveness to insulin via IRS-1 has
shown to be associated with upregulation of P2Y12 signal-
ng, it cannot be excluded that this might also affect other
latelet signaling pathways, commonly upregulated in plate-
ets from patients with DM (12,37). In fact, IRS-1 is a
ajor tyrosine phosphorylated substrate for the insulin
eceptor acting as a multisite docking protein to several Src
omology 2 domains containing proteins, such as the
egulatory subunits of phosphatidylinositol 3-kinase
PI3K)—which are key in multiple platelet activation pro-
esses (13). This is in line with the fact that patients with
PR to ADP frequently have HPR to non-purinergic
timuli (i.e., collagen), indicative of an overall hyper-reactive
latelet phenotype, which might also be a better predictor of
dverse outcomes, as also suggested by this study (9,38,39).
his might contribute to the elevated prevalence of reduced
spirin-induced antiplatelet effects when measured by
yclooxygenase-1 nonspecific assays in patients with DM
6,40–42). Furthermore, patients with DM presenting with
hyper-reactive platelet phenotype have been shown to
ave a marked increase in platelet reactivity after clopidogrel
ithdrawal (43). Overall, these findings might explain why
ur long-term survival curves continue to diverge over time,
articularly while patients were only taking aspirin therapy.
hether prolonging clopidogrel therapy in patients defined
o be at higher risk on the basis of our laboratory findings
ould have led to improved clinical outcomes cannot be
xtrapolated from this study. It might be hypothesized that
atients who are type 2 DM carriers of the C allele of the
RS-1 rs956115 tag SNP, who our study demonstrated to
ave a hyper-reactive platelet phenotype and worse out-
omes, might benefit from more potent antithrombotic
egimens. These might include high-dose clopidogrel (44),
riple therapy (aspirin, clopidogrel, and cilostazol) (45), or
ovel and more potent P2Y12 receptor antagonists (46,47).
Among the latter, prasugrel has been shown to be associated
with better clinical outcomes, particularly in patients with
DM (48). However, atherothrombotic event rates continue
to be high in patients with DM, which might be attributed
to upregulation of other pivotal platelet signaling pathways
triggering thrombosis, suggesting the need for antiplatelet
agents that are able to block these alternative pathways
(46,49).
In summary, heterogeneous antiplatelet drug effects are
observed in type 2 DM patients, and patients with HPR
have a greater risk of recurrent events. The C allele of the
rs956115 polymorphism of IRS-1, observed in approxi-
mately 20% of patients, is independently associated with
HPR and enhanced long-term cardiovascular risk. These
findings might explain why in clinical practice, although
type 2 DM represents per se a high-risk cohort, some
patients have worse outcomes than others and might war-
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vations provide further insights on how pharmacogenetic
analyses might identify patients with type 2 DM at different
cardiovascular risk, suggesting the need for personalized
treatment strategies in these patients.
Study limitations. Several cutoff values of HPR have been
defined in the published data, although these might vary
according to the specific population under investigation or
timing from an acute event, among many other variables
(50). Because this study selectively investigated a population
with DM in a period remote from their PCI for which there
is limited data on cutoff values of HPR, in agreement with
prior investigations, we considered a ROC analysis to define
the value with the highest sensitivity and highest specificity
in our study population (50). Furthermore, it might be
argued that, although marker rs956115 is in LD with
rs1896832, only rs956115 showed a significant association
with outcome measures. This can be explained by the degree
of LD between the 2 markers. In fact, although the C allele
of rs956115 is fully associated with the A allele of
rs1896832, the opposite is not true, because most of the A
alleles of marker rs1896832 are not associated with the C
allele of marker rs956115 (approximately 88%). This is
because alleles at 2 different markers have different frequen-
cies and thus not the same as in the case of an absolute LD.
Because in the association analysis of marker rs1896832
only a proportion of A alleles has a different effect compared
with the other G alleles (those in linkage with the C allele
of marker rs956115), a larger sample of individuals as
reported by others would be required to detect a significant
effect of allele A (51). An independent validation would also
allow a better estimation of allelic frequencies of the IRS-1
gene, which in our study showed some differences, likely
attributable to the sample size, in patients with and without
DM. Although the advantage of using a study population
without very strong LD between SNP to map causal
variants might be a good strategy to identify portions of
genes implicated in the susceptibility of the phenotypes of
interest, indeed sequencing of the entire gene and promoter
region is the definitive approach to identify all the important
sequence variants. Ultimately, in the logistic regression for
statistical adjustment, the potential for overfitting of the
model may not be excluded, because the selection of the
variables was based on clinical judgment by entering all the
covariates that might impact the degree of platelet
aggregation.
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